Patient-Centeredness in the Design of Clinical Trials

Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making....

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Value in health Ročník 17; číslo 4; s. 471 - 475
Hlavní autori:	Mullins, C. Daniel, Vandigo, Joseph, Zheng, Zhiyuan, Wicks, Paul
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	New York, NY Elsevier Inc 01.06.2014 Elsevier
Predmet:	adaptive Attitudes Bayes Theorem Bayesian Biological and medical sciences Clinical trials Clinical Trials as Topic Decision making General aspects Health care Humans Internal Medicine Learning Medical sciences Miscellaneous Patient Participation patient-centered Patient-Centered Care Personnel Planification. Prevention (methods). Intervention. Evaluation pragmatic Public Health Public health. Hygiene Public health. Hygiene-occupational medicine Research Design trial design patient-centered adaptive trial design pragmatic Bayesian Patient-centered approach Goal Statistical analysis Clinical trial
ISSN:	1098-3015, 1524-4733, 1524-4733
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel.
AbstractList	AbstractEvidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel. Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel. Adapted from the source document. Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel. Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a pre-specified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. In order to achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel. Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel.Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating in clinical trials meaningless or disempowering. Moreover, people often do not incorporate trial results directly into their decision making. The lack of patient centeredness in clinical trials may be partially addressed through trial design. For example, Bayesian adaptive trials designed to adjust in a prespecified manner to changes in clinical practice could motivate people and their health care providers to view clinical trials as more applicable to real-world clinical decisions. The way in which clinical trials are designed can transform the evidence generation process to be more patient centered, providing people with an incentive to participate or continue participating in clinical trials. To achieve the transformation to patient-centeredness in clinical trial decisions, however, there is a need for transparent and reliable methods and education of trial investigators and site personnel.
Author	Vandigo, Joseph Wicks, Paul Mullins, C. Daniel Zheng, Zhiyuan
AuthorAffiliation	2 PatientsLikeMe Inc., Research & Development, Cambridge, MA, USA 1 University of Maryland School of Pharmacy, Pharmaceutical Health Services Research Department, Baltimore, MD, USA 3 American Cancer Society, Surveillance and Health Services Research Program, Atlanta, GA, USA
AuthorAffiliation_xml	– name: 3 American Cancer Society, Surveillance and Health Services Research Program, Atlanta, GA, USA – name: 1 University of Maryland School of Pharmacy, Pharmaceutical Health Services Research Department, Baltimore, MD, USA – name: 2 PatientsLikeMe Inc., Research & Development, Cambridge, MA, USA
Author_xml	– sequence: 1 givenname: C. Daniel surname: Mullins fullname: Mullins, C. Daniel organization: Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA – sequence: 2 givenname: Joseph surname: Vandigo fullname: Vandigo, Joseph email: jvandigo@umaryland.edu organization: Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA – sequence: 3 givenname: Zhiyuan surname: Zheng fullname: Zheng, Zhiyuan organization: Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA – sequence: 4 givenname: Paul surname: Wicks fullname: Wicks, Paul organization: PatientsLikeMe, Inc., Research & Development, Cambridge, MA, USA
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28664000$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24969009$$D View this record in MEDLINE/PubMed
BookMark	eNqNUl1rFDEUDVKx7eof8EHmRfBlxnzPRKQga6tCQcH6fMlm7rQZZzNtMrvQf2-G3fpRsPqSG8g5J_fec47JQRgDEvKc0YpRpl_3Vb-1Q8UpkxXlFWX8ETliistS1kIc5Ds1TSkoU4fkOKWeUqoFV0_IIZdGG0rNEVFf7OQxTOUyHxixDZhS4UMxXWHxHpO_DMXYFcvBB-_sUFxEb4f0lDzucsFn-7og385OL5Yfy_PPHz4t352XThs5lZ1aUWs0KlszKRtpDQqmnRYOdcM0by1d1Y2UNTfOKsEMZah1W2cCZ5YKsSAnO93rzWqNrcs9RjvAdfRrG29htB7-fAn-Ci7HLUhpalXTLPBqLxDHmw2mCdY-ORwGG3DcJGBKNcao2sj_gEomasnVrPri97Z-9nO31gx4uQfYlLfWRRucT79wjdYyu5FxzQ7n4phSxA6cn7Ih4zyNH4BRmJ2GHmanYXYaKIfsdKbye9Q79QdJb3ckzKZtPUZILrvvsPUR3QTt6B-mn9yju30uvuMtpn7cxJDjAAxSJsDXOX9z_Ng87JzJBXnzd4F__f4DYxTn0w
CitedBy_id	crossref_primary_10_1111_hex_12583 crossref_primary_10_1016_j_clinthera_2017_08_016 crossref_primary_10_1007_s00268_023_07124_z crossref_primary_10_3233_JHD_180328 crossref_primary_10_1097_WCO_0000000000000823 crossref_primary_10_3390_biom13010138 crossref_primary_10_1089_hum_2023_157 crossref_primary_10_1177_23814683211021380 crossref_primary_10_1016_j_jad_2014_10_005 crossref_primary_10_1186_s13063_020_4137_2 crossref_primary_10_1371_journal_pone_0295080 crossref_primary_10_1111_wrr_12872 crossref_primary_10_1177_1740774520956578 crossref_primary_10_3389_fneur_2018_00627 crossref_primary_10_1002_sim_8776 crossref_primary_10_1371_journal_pgph_0004372 crossref_primary_10_1016_j_conctc_2020_100608 crossref_primary_10_1002_cncr_32455 crossref_primary_10_1186_s13023_018_0931_2 crossref_primary_10_1186_s40900_016_0047_6 crossref_primary_10_1016_j_waojou_2023_100769 crossref_primary_10_2217_cer_2018_0026 crossref_primary_10_1186_s13063_018_2578_7 crossref_primary_10_1159_000492502 crossref_primary_10_2147_OPTH_S241928 crossref_primary_10_3389_fpsyt_2021_661233 crossref_primary_10_1007_s13142_017_0487_z crossref_primary_10_1186_s13063_020_4129_2 crossref_primary_10_3389_fphar_2022_969778 crossref_primary_10_2196_13597 crossref_primary_10_1038_s41416_024_02695_7 crossref_primary_10_1111_cts_12863 crossref_primary_10_1177_2168479017706405 crossref_primary_10_2215_CJN_08370816 crossref_primary_10_1080_14737175_2022_2161893 crossref_primary_10_1016_j_ahj_2014_10_002 crossref_primary_10_1021_acssensors_4c03292 crossref_primary_10_1136_bmj_m122 crossref_primary_10_1093_fampra_cmaa134 crossref_primary_10_3389_fphar_2020_00043 crossref_primary_10_1080_10543406_2024_2359149 crossref_primary_10_1093_rheumatology_kex390_068 crossref_primary_10_1186_s12938_018_0553_x crossref_primary_10_1371_journal_pmed_1002049 crossref_primary_10_1177_10398562221121215 crossref_primary_10_1177_2050312120977116 crossref_primary_10_1111_bcp_14240 crossref_primary_10_2196_17026 crossref_primary_10_1097_NCC_0000000000000702 crossref_primary_10_1586_14737167_2016_1163222 crossref_primary_10_1186_s13023_017_0601_9 crossref_primary_10_1007_s43441_020_00179_3 crossref_primary_10_3414_ME15_02_0005 crossref_primary_10_1136_bmjopen_2022_064159 crossref_primary_10_1016_j_ejca_2021_04_012 crossref_primary_10_1016_j_jclinepi_2021_01_014 crossref_primary_10_3390_healthcare9060665 crossref_primary_10_1111_hex_13304 crossref_primary_10_1186_s12872_023_03047_8 crossref_primary_10_1177_1877718X251315645 crossref_primary_10_1186_s13023_020_01400_0 crossref_primary_10_1177_2168479018817517
Cites_doi	10.1038/nrd1927 10.1111/j.1365-2702.2009.03041.x 10.1001/jama.2012.442 10.4065/84.3.243 10.2196/jmir.2127 10.1016/j.jclinepi.2010.12.019 10.1007/978-1-4419-0284-9_18 10.1093/intqhc/10.4.319 10.1038/clpt.2013.218 10.1038/nrd3174 10.1186/1750-1172-3-11 10.1136/bmj.316.7127.285 10.1111/j.1525-1497.2005.0178.x
ContentType	Journal Article
Copyright	2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2015 INIST-CNRS Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier 2014
Copyright_xml	– notice: 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – notice: 2015 INIST-CNRS – notice: Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved. – notice: 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier 2014
DBID	6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7QJ 5PM
DOI	10.1016/j.jval.2014.02.012
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Applied Social Sciences Index & Abstracts (ASSIA) PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA)
DatabaseTitleList	Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology Public Health
EISSN	1524-4733
EndPage	475
ExternalDocumentID	PMC4497570 24969009 28664000 10_1016_j_jval_2014_02_012 S1098301514000473 1_s2_0_S1098301514000473
Genre	Research Support, U.S. Gov't, P.H.S Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: AHRQ HHS grantid: R24 HS022135 – fundername: NHLBI NIH HHS grantid: 1RC4HL106363-01 – fundername: NHLBI NIH HHS grantid: RC4 HL106363 – fundername: AHRQ HHS grantid: R24HS022135
GroupedDBID	--- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6PF 7-5 7PT 8-1 8P~ 8UM AAEDT AAEDW AAFJI AAFWJ AAIKJ AAKOC AALRI AAMMB AAOAW AAPFB AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACLOT ACPRK ACRLP ACRPL ACUHS ACVFH ACXQS ADBBV ADCNI ADEZE ADFHU ADMUD ADNMO ADVLN AEBSH AEFGJ AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AEYQN AFBPY AFEBI AFJKZ AFPUW AFRHN AFTJW AFXIZ AFZJQ AGHFR AGQPQ AGTHC AGUBO AGXDD AGYEJ AIDQK AIDYY AIEXJ AIGII AIIAU AIIUN AIKHN AITUG AJAOE AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AOMHK APXCP ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EFKBS EFLBG EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM LH4 M41 MO0 N9A O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SV3 T5K TEORI TUS W99 WIN WYUIH XG1 YFH Z5R ~G- ~HD 0SF 6I. AACTN AAFTH AAHHS ABVKL ACCFJ AEEZP AEQDE AFCTW AFKWA AIWBW AJBDE AJOXV AMFUW NCXOZ RIG SUPJJ AAIAV ABLVK ABYKQ AJBFU AKYCK IXIXF LCYCR AAYXX ALUQN CITATION O8X IQODW AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 7QJ 5PM
ID	FETCH-LOGICAL-c694t-f5b0a96e5a714484a9e316c63ce68162da0b7844729ca531901e66d7e5a21a033
ISICitedReferencesCount	64
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000341082900022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-3015 1524-4733
IngestDate	Tue Sep 30 16:59:28 EDT 2025 Sun Sep 28 03:25:41 EDT 2025 Sat Sep 27 20:33:21 EDT 2025 Mon Jul 21 05:59:41 EDT 2025 Wed Apr 02 07:25:12 EDT 2025 Sat Nov 29 05:54:01 EST 2025 Tue Nov 18 19:50:35 EST 2025 Fri Feb 23 02:33:42 EST 2024 Sun Feb 23 10:18:51 EST 2025 Tue Oct 14 19:37:58 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	patient-centered adaptive trial design pragmatic Bayesian Patient-centered approach Goal Statistical analysis Clinical trial
Language	English
License	http://creativecommons.org/licenses/by-nc-nd/4.0 CC BY 4.0 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c694t-f5b0a96e5a714484a9e316c63ce68162da0b7844729ca531901e66d7e5a21a033
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://www.clinicalkey.es/playcontent/1-s2.0-S1098301514000473
PMID	24969009
PQID	1541374250
PQPubID	23479
PageCount	5
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_4497570 proquest_miscellaneous_1558995794 proquest_miscellaneous_1541374250 pubmed_primary_24969009 pascalfrancis_primary_28664000 crossref_citationtrail_10_1016_j_jval_2014_02_012 crossref_primary_10_1016_j_jval_2014_02_012 elsevier_sciencedirect_doi_10_1016_j_jval_2014_02_012 elsevier_clinicalkeyesjournals_1_s2_0_S1098301514000473 elsevier_clinicalkey_doi_10_1016_j_jval_2014_02_012
PublicationCentury	2000
PublicationDate	2014-06-01
PublicationDateYYYYMMDD	2014-06-01
PublicationDate_xml	– month: 06 year: 2014 text: 2014-06-01 day: 01
PublicationDecade	2010
PublicationPlace	New York, NY
PublicationPlace_xml	– name: New York, NY – name: United States
PublicationTitle	Value in health
PublicationTitleAlternate	Value Health
PublicationYear	2014
Publisher	Elsevier Inc Elsevier
Publisher_xml	– name: Elsevier Inc – name: Elsevier
References	Berry (bib10) 2006; 5 Verheggen, Nieman, Reerink, Kok (bib3) 1998; 10 U.S. Food and Drug Administration, Center for Devices and Radiological Health. Guidance for the use of Bayesian statistics in medical device clinical trials—guidance for industry and FDA staff. Available from Roland, Torgerson (bib8) 1998; 316 A New Definition of Patient Engagement: What is Engagement and Why Is It Important? Washington, DC: Center for Advancing Health, 2010. Available from Sood, Prasad, Chhatwani (bib4) 2009; 84 Chow SC, Chang M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008;3:11. Available from [Accessed November 21, 2013]. Patient-Centered Outcome Research Institute. Patient-Centered Outcomes Research. Washington, DC: Patient-Centered Outcome Research Institute, 2012. Available from Marina, Bielack, Whelan (bib15) 2009; 152 Gupta, Faughnan, Tomlinson, Bayoumi (bib17) 2011; 64 Kesselheim, Gagne (bib16) 2014; 95 Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006;40:425–35. Available from [Accessed October 4, 2012]. Davis, Schoenbaum, Audet (bib7) 2005; 20 Nakamura, Bromberg, Bhargava (bib9) 2012; 14 Gul, Ali (bib5) 2010; 19 Collins (bib13) 2011; 6 Mullins, Abdulhalim, Lavallee (bib2) 2012; 307 [Accessed November 7, 2013]. Jones (bib11) 2010; 9 Berry (10.1016/j.jval.2014.02.012_bib10) 2006; 5 10.1016/j.jval.2014.02.012_bib14 10.1016/j.jval.2014.02.012_bib1 10.1016/j.jval.2014.02.012_bib12 Nakamura (10.1016/j.jval.2014.02.012_bib9) 2012; 14 10.1016/j.jval.2014.02.012_bib18 10.1016/j.jval.2014.02.012_bib6 Sood (10.1016/j.jval.2014.02.012_bib4) 2009; 84 Davis (10.1016/j.jval.2014.02.012_bib7) 2005; 20 Marina (10.1016/j.jval.2014.02.012_bib15) 2009; 152 Verheggen (10.1016/j.jval.2014.02.012_bib3) 1998; 10 Collins (10.1016/j.jval.2014.02.012_bib13) 2011; 6 Mullins (10.1016/j.jval.2014.02.012_bib2) 2012; 307 Jones (10.1016/j.jval.2014.02.012_bib11) 2010; 9 Kesselheim (10.1016/j.jval.2014.02.012_bib16) 2014; 95 Gul (10.1016/j.jval.2014.02.012_bib5) 2010; 19 Roland (10.1016/j.jval.2014.02.012_bib8) 1998; 316 Gupta (10.1016/j.jval.2014.02.012_bib17) 2011; 64 16485344 - Nat Rev Drug Discov. 2006 Jan;5(1):27-36 20414200 - Nat Rev Drug Discov. 2010 May;9(5):345-8 22721865 - J Med Internet Res. 2012;14(3):e90 18454853 - Orphanet J Rare Dis. 2008;3:11 21530171 - J Clin Epidemiol. 2011 Oct;64(10):1085-94 20500260 - J Clin Nurs. 2010 Jan;19(1-2):227-33 19252111 - Mayo Clin Proc. 2009 Mar;84(3):243-7 20213400 - Cancer Treat Res. 2009;152:339-53 9472515 - BMJ. 1998 Jan 24;316(7127):285 22511684 - JAMA. 2012 Apr 18;307(15):1587-8 16191145 - J Gen Intern Med. 2005 Oct;20(10):953-7 9835248 - Int J Qual Health Care. 1998 Aug;10(4):319-30
References_xml	– reference: . [Accessed October 4, 2012]. – volume: 20 start-page: 953 year: 2005 end-page: 957 ident: bib7 article-title: A 2020 vision of patient-centered primary care publication-title: J Gen Intern Med – volume: 14 start-page: e90 year: 2012 ident: bib9 article-title: Mining online social network data for biomedical research: a comparison of clinicians’ and patients’ perceptions about amyotrophic lateral sclerosis treatments publication-title: J Med Internet Res – volume: 9 start-page: 345 year: 2010 end-page: 348 ident: bib11 article-title: Adaptive trials receive boost publication-title: Nat Rev Drug Discov – volume: 307 start-page: 1587 year: 2012 end-page: 1588 ident: bib2 article-title: Continuous patient engagement in comparative effectiveness research publication-title: JAMA – volume: 10 start-page: 319 year: 1998 end-page: 330 ident: bib3 article-title: Patient satisfaction with clinical trial participation publication-title: Int J Qual Health Care – reference: Dragalin V. Adaptive designs: terminology and classification. Drug Inf J 2006;40:425–35. Available from: – reference: A New Definition of Patient Engagement: What is Engagement and Why Is It Important? Washington, DC: Center for Advancing Health, 2010. Available from: – reference: . [Accessed November 7, 2013]. – volume: 5 start-page: 27 year: 2006 end-page: 36 ident: bib10 article-title: Bayesian clinical trials publication-title: Nat Rev Drug Discov – volume: 316 start-page: 285 year: 1998 ident: bib8 article-title: Understanding controlled trials: what are pragmatic trials? publication-title: BMJ – volume: 64 start-page: 1085 year: 2011 end-page: 1094 ident: bib17 article-title: A framework for applying unfamiliar trial designs in studies of rare diseases publication-title: J Clin Epidemiol – reference: Chow SC, Chang M. Adaptive design methods in clinical trials—a review. Orphanet J Rare Dis 2008;3:11. Available from: – volume: 84 start-page: 243 year: 2009 end-page: 247 ident: bib4 article-title: Patients’ attitudes and preferences about participation and recruitment strategies in clinical trials publication-title: Mayo Clin Proc – volume: 19 start-page: 227 year: 2010 end-page: 233 ident: bib5 article-title: Clinical trials: the challenge of recruitment and retention of participants publication-title: J Clin Nurs – reference: U.S. Food and Drug Administration, Center for Devices and Radiological Health. Guidance for the use of Bayesian statistics in medical device clinical trials—guidance for industry and FDA staff. Available from: – volume: 6 start-page: 2 year: 2011 end-page: 3 ident: bib13 article-title: From the NIH director: the importance of clinical trials publication-title: NIH MedlinePlus – reference: . [Accessed November 21, 2013]. – reference: Patient-Centered Outcome Research Institute. Patient-Centered Outcomes Research. Washington, DC: Patient-Centered Outcome Research Institute, 2012. Available from: – volume: 152 start-page: 339 year: 2009 end-page: 353 ident: bib15 article-title: International collaboration is feasible in trials for rare conditions: the EURAMOS experience publication-title: Cancer Treat Res – volume: 95 start-page: 265 year: 2014 end-page: 268 ident: bib16 article-title: Strategies for post-market surveillance of drugs for rare diseases publication-title: Clin Pharmacol Therapeut – ident: 10.1016/j.jval.2014.02.012_bib12 – volume: 5 start-page: 27 year: 2006 ident: 10.1016/j.jval.2014.02.012_bib10 article-title: Bayesian clinical trials publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1927 – ident: 10.1016/j.jval.2014.02.012_bib14 – volume: 19 start-page: 227 year: 2010 ident: 10.1016/j.jval.2014.02.012_bib5 article-title: Clinical trials: the challenge of recruitment and retention of participants publication-title: J Clin Nurs doi: 10.1111/j.1365-2702.2009.03041.x – volume: 307 start-page: 1587 year: 2012 ident: 10.1016/j.jval.2014.02.012_bib2 article-title: Continuous patient engagement in comparative effectiveness research publication-title: JAMA doi: 10.1001/jama.2012.442 – volume: 84 start-page: 243 year: 2009 ident: 10.1016/j.jval.2014.02.012_bib4 article-title: Patients’ attitudes and preferences about participation and recruitment strategies in clinical trials publication-title: Mayo Clin Proc doi: 10.4065/84.3.243 – volume: 14 start-page: e90 year: 2012 ident: 10.1016/j.jval.2014.02.012_bib9 article-title: Mining online social network data for biomedical research: a comparison of clinicians’ and patients’ perceptions about amyotrophic lateral sclerosis treatments publication-title: J Med Internet Res doi: 10.2196/jmir.2127 – volume: 64 start-page: 1085 year: 2011 ident: 10.1016/j.jval.2014.02.012_bib17 article-title: A framework for applying unfamiliar trial designs in studies of rare diseases publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.12.019 – volume: 152 start-page: 339 year: 2009 ident: 10.1016/j.jval.2014.02.012_bib15 article-title: International collaboration is feasible in trials for rare conditions: the EURAMOS experience publication-title: Cancer Treat Res doi: 10.1007/978-1-4419-0284-9_18 – ident: 10.1016/j.jval.2014.02.012_bib1 – volume: 10 start-page: 319 year: 1998 ident: 10.1016/j.jval.2014.02.012_bib3 article-title: Patient satisfaction with clinical trial participation publication-title: Int J Qual Health Care doi: 10.1093/intqhc/10.4.319 – volume: 95 start-page: 265 year: 2014 ident: 10.1016/j.jval.2014.02.012_bib16 article-title: Strategies for post-market surveillance of drugs for rare diseases publication-title: Clin Pharmacol Therapeut doi: 10.1038/clpt.2013.218 – volume: 9 start-page: 345 year: 2010 ident: 10.1016/j.jval.2014.02.012_bib11 article-title: Adaptive trials receive boost publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3174 – ident: 10.1016/j.jval.2014.02.012_bib6 – ident: 10.1016/j.jval.2014.02.012_bib18 doi: 10.1186/1750-1172-3-11 – volume: 316 start-page: 285 year: 1998 ident: 10.1016/j.jval.2014.02.012_bib8 article-title: Understanding controlled trials: what are pragmatic trials? publication-title: BMJ doi: 10.1136/bmj.316.7127.285 – volume: 6 start-page: 2 year: 2011 ident: 10.1016/j.jval.2014.02.012_bib13 article-title: From the NIH director: the importance of clinical trials publication-title: NIH MedlinePlus – volume: 20 start-page: 953 year: 2005 ident: 10.1016/j.jval.2014.02.012_bib7 article-title: A 2020 vision of patient-centered primary care publication-title: J Gen Intern Med doi: 10.1111/j.1525-1497.2005.0178.x – reference: 9472515 - BMJ. 1998 Jan 24;316(7127):285 – reference: 21530171 - J Clin Epidemiol. 2011 Oct;64(10):1085-94 – reference: 19252111 - Mayo Clin Proc. 2009 Mar;84(3):243-7 – reference: 22721865 - J Med Internet Res. 2012;14(3):e90 – reference: 9835248 - Int J Qual Health Care. 1998 Aug;10(4):319-30 – reference: 22511684 - JAMA. 2012 Apr 18;307(15):1587-8 – reference: 20414200 - Nat Rev Drug Discov. 2010 May;9(5):345-8 – reference: 16485344 - Nat Rev Drug Discov. 2006 Jan;5(1):27-36 – reference: 18454853 - Orphanet J Rare Dis. 2008;3:11 – reference: 16191145 - J Gen Intern Med. 2005 Oct;20(10):953-7 – reference: 20500260 - J Clin Nurs. 2010 Jan;19(1-2):227-33 – reference: 20213400 - Cancer Treat Res. 2009;152:339-53
SSID	ssj0006325
Score	2.3440287
Snippet	Evidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find participating... AbstractEvidence from clinical trials should contribute to informed decision making and a learning health care system. People frequently, however, find...
SourceID	pubmedcentral proquest pubmed pascalfrancis crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	471
SubjectTerms	adaptive Attitudes Bayes Theorem Bayesian Biological and medical sciences Clinical trials Clinical Trials as Topic Decision making General aspects Health care Humans Internal Medicine Learning Medical sciences Miscellaneous Patient Participation patient-centered Patient-Centered Care Personnel Planification. Prevention (methods). Intervention. Evaluation pragmatic Public Health Public health. Hygiene Public health. Hygiene-occupational medicine Research Design trial design
Title	Patient-Centeredness in the Design of Clinical Trials
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1098301514000473 https://www.clinicalkey.es/playcontent/1-s2.0-S1098301514000473 https://dx.doi.org/10.1016/j.jval.2014.02.012 https://www.ncbi.nlm.nih.gov/pubmed/24969009 https://www.proquest.com/docview/1541374250 https://www.proquest.com/docview/1558995794 https://pubmed.ncbi.nlm.nih.gov/PMC4497570
Volume	17
WOSCitedRecordID	wos000341082900022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1524-4733 dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0006325 issn: 1098-3015 databaseCode: AIEXJ dateStart: 19980501 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdYhxASQjC-ykcVJNQXlilxHH88TqgToDIq0ZWKF8tNHa1lSsvSovW_5xw7STtKGQ-8RFFi5-t-Pt_Fd79D6E0wxpjhUeQznQpwUEYBjLmU-YKEKjbrVKwg9Rl02ekpHw5Fz2Vc50U5AZZl_OpKzP-rqOEYCNukzv6DuKuLwgHYB6HDFsQO2xsJvmeZUn0TdmkKcRa6zEUzjot4jSKUvMyILMp25Os26kBdLAsqEZsjWYvE0HdbRgKXmV6eGhRsr7O1FYXqd7S2uuTb-WS1rIH4dZJ8zzcCE92Ph5DUAVKlrsTEJ8zyWBzpLcdKBcvWgETWtCWx1Vd-0-L2h8L0aApf30TfkYJW1YVbb1Bmn36WJ2fdrux3hv32_IdvqomZVXdXWmUP7WMWC95A-8cfOsOP1RxNo6Icb_W4Lp3KRv5dv-2fTJZ7c5WDoFJbAWWbi3I90nbNdOk_QPedz-EdW6w8RLd0doDufHJRFQeo3bP85atDr1-n4-WHXtvr1czmq0co3oYtb5J5gC3PYsubpV6JLc9i6zE6O-n03733Xd0NP6GCLPw0HgVKUB0rBu42J0roKKQJjRJNYfjisQpGjBMCflmijA4PQk3pmEEHHKogip6gRjbL9DPkYYV1SpXm8KFJgqkA6xCPEkHiVI05ZU0Ulp9WJo6U3tRGuZBl9OFUGnFIIw4ZYAniaKK3VZ-5pWTZ2ToqJSbL14fpUQLWdvZi23rp3A30XIYyh5bySxgIDpMk-B3GPWJRE8VVT2fEWuP0r3dsbcCpejXMKTXXbqLXJb4kTAFmXU9leraER4nBEmUw-e5sE3NhluRJEz21mKzvQAQV4GvBS2-gtWpgKOg3z2ST84KKnhDBYhY8v8GzvUB3ay3yEjUWl0v9Ct1Ofi4m-WUL7bEhb7lh-gtDHPmp
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patient-centeredness+in+the+design+of+clinical+trials&rft.jtitle=Value+in+health&rft.au=Mullins%2C+C+Daniel&rft.au=Vandigo%2C+Joseph&rft.au=Zheng%2C+Zhiyuan&rft.au=Wicks%2C+Paul&rft.date=2014-06-01&rft.issn=1524-4733&rft.eissn=1524-4733&rft.volume=17&rft.issue=4&rft.spage=471&rft_id=info:doi/10.1016%2Fj.jval.2014.02.012&rft.externalDBID=NO_FULL_TEXT
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10983015%2FS1098301514X00045%2Fcov150h.gif